The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
and so we you know talked with his doctors about the possibility of enrolling him in one of the Kuda trials there was one going on I think at Stanford and you know the thinking being well you would want to Target a checkpoint inhibitor against somebody who has a lot of mutations and even though typically we don't see that in pancreatic cancer his is a unique variant of it because it's based on this
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
so we're able to get him into a trial of katruda
i had just remembered reading a paper about how patients with lynch were more likely to have checkpoint mutations
so there are some situations like the micro satellite unstable uh cancers colon cancer other other kinds of cancer types Lynch syndrome uh but we didn't understand that with mutations that were involved at that point and I don't remember ever treating a patient with Lynch syndrome you're right they would have a very large number of mutations
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.